Discovery of (E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives as inhibitors for PTK6.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2014-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2014.08.036PMID 25205190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein-tyrosine Kinase 6 Promotes Peripheral Adhesion Complex Formation and Cell Migration by Phosphorylating p130 CRK-associated Substrate*

  2011cited by this paper
• PTK6 Inhibits Down-regulation of EGF Receptor through Phosphorylation of ARAP1*

  2010cited by this paper
• Protein Tyrosine Kinase 6 Directly Phosphorylates AKT and Promotes AKT Activation in Response to Epidermal Growth Factor

  2010cited by this paper
• Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.

  2008cited by this paper
• The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary

  2006cited by this paper
• An Intramolecular Interaction between SH2-Kinase Linker and Kinase Domain Is Essential for the Catalytic Activity of Protein-tyrosine Kinase-6*

  2005cited by this paper
• The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges

  2004cited by this paper
• Identification of tyrosine kinases overexpressed in head and neck cancer.

  2004cited by this paper
• Brk Activates Rac1 and Promotes Cell Migration and Invasion by Phosphorylating Paxillin

  2004cited by this paper
• c-erbB-2 in breast cancer: development of a clinically useful marker.

  2002cited by this paper
• The p53 pathway in breast cancer

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK

  2000cited by this paper
• BRK/Sik expression in the gastrointestinal tract and in colon tumors.

  1999cited by this paper
• Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase.

  1998cited by this paper
• BRK tyrosine kinase expression in a high proportion of human breast carcinomas

  1997cited by this paper
• Assignment of the human PTK6 gene encoding a non-receptor protein tyrosine kinase to 20q13.3 by fluorescence in situ hybridization.

  1997cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

  1997cited by this paper
• Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.

  1996cited by this paper
• Brk, a Breast Tumor-derived Non-receptor Protein-tyrosine Kinase, Sensitizes Mammary Epithelial Cells to Epidermal Growth Factor*

  1996cited by this paper
• Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours.

  1994cited by this paper
• Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity.

  1992cited by this paper

• Benzimidazolone conjugated biscoumarins: Synthesis, molecular docking studies, urease, lipase, and acetylcholinesterase inhibitory activities

  2025cites this paper
• Prognostic impact of PTK6 expression in triple negative breast cancer

  2023cites this paper
• Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models

  2021cites this paper
• Synthesis and biological evaluation of benzimidazolone bridged triheterocyclic compounds

  2021cites this paper
• Putting the BRK on breast cancer: From molecular target to therapeutics

  2021influential citation
• Targeting protein tyrosine kinase 6 in cancer.

  2020cites this paper
• 1 BRK ” ing ” Down All We Know About PTK 6 in Breast Cancer 2

  2018influential citation
• Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

  2018cites this paper
• The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.

  2017cites this paper
• Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.

  2017cites this paper
• PTK6 Localized at the Plasma Membrane Promotes Cell Proliferation and MigratiOn Through Phosphorylation of Eps8

  2017cites this paper
• Synthesis, antifungal and antitumor activity of two new types of imidazolin-2-ones.

  2017cites this paper
• The associated pyrazolopyrimidines PP 1 and PP 2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation

  2017cites this paper
• Access to N-thioalkenyl and N-(o-thio)aryl-benzimidazol-2-ones by ring opening of thiazolobenzimidazolium and benzimidazobenzothiazolium salts and C-O bond cleavage of an alkoxide.

  2015cites this paper
• PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim

  2015cites this paper